Neuregulins: Versatile growth and differentiation factors in nervous system development and human disease

被引:122
作者
Esper, Raymond M.
Pankonin, Mark S.
Loeb, Jeffrey A.
机构
[1] Wayne State Univ, Dept Neurol, Detroit, MI 48201 USA
[2] Wayne State Univ, Ctr Mol Med & Genet, Detroit, MI 48201 USA
关键词
neuregulin; neurotrophic factor; multiple sclerosis; schizophrenia; development;
D O I
10.1016/j.brainresrev.2005.11.006
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The neuregulins are a family of growth and differentiation factors with a wide range of functions in the nervous system. The power and diversity of the neuregulin signaling system comes in part from a large number of alternatively-spliced forms of the NRG1 gene that can produce both soluble and membrane-bound forms. The soluble forms of neuregulin are unique from other factors in that they have a structurally distinct heparin-binding domain that targets and potentiates its actions. In addition, a finely tuned, bidirectional mechanism regulates when and where neuregulin is released from neurons in response to neurotrophic factors produced by both neuronal targets and supporting glial cells. Together, this produces a balanced intercellular signaling system that can be localized to distinct regions for both normal development and maintenance of the mature nervous system. Recent evidence suggests that neuregulin signaling plays important roles in many neurological disorders including multiple sclerosis, traumatic brain and spinal cord injury, peripheral neuropathy, and schizophrenia. Here, we review the basic biology of neuregulins and relate this to research suggesting their involvement with and potential therapeutic uses for neurological disorders. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:161 / 175
页数:15
相关论文
共 220 条
  • [1] Adlkofer K, 2000, GLIA, V29, P104, DOI 10.1002/(SICI)1098-1136(20000115)29:2<104::AID-GLIA2>3.0.CO
  • [2] 2-2
  • [3] Akbarian S, 1996, J NEUROSCI, V16, P19
  • [4] APFEL SC, 1995, BAILLIERE CLIN NEUR, V4, P593
  • [5] Nerve regeneration in diabetic neuropathy
    Apfel, SC
    [J]. DIABETES OBESITY & METABOLISM, 1999, 1 (01) : 3 - 11
  • [6] Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy - A randomized controled trial
    Apfel, SC
    Schwartz, S
    Adornato, BT
    Freeman, R
    Biton, V
    Rendell, M
    Vinik, A
    Giuliani, M
    Stevens, JC
    Barbano, R
    Dyck, PJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (17): : 2215 - 2221
  • [7] Apfel SC, 1996, CIBA F SYMP, V196, P98
  • [8] Neurotrophic factor therapy - Prospects and problems
    Apfel, SC
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2001, 39 (04) : 351 - 355
  • [9] Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy
    Apfel, SC
    Kessler, JA
    Adornato, BT
    Litchy, WJ
    Sanders, C
    Rask, CA
    [J]. NEUROLOGY, 1998, 51 (03) : 695 - 702
  • [10] Apfel SC, 2002, INT REV NEUROBIOL, V50, P393